title: Is it necessary to check outcomes to improve quality of care? The example of anemia management.
abstract: The aim of this study was to verify the importance of continuously monitoring the level of adherence to the anemia guideline recommendations in order to improve not only quality of care but also patient safety. Data presented in this investigation were gained through the FME database EuCliD which contains the clinical data of over 24,000 prevalent patients under treatment at the time of the analysis in 344 dialysis centres in 15 countries. Patient data from 4 countries (United Kingdom, Turkey, Italy, Portugal) was used for this study. The parameter selected was anemia control. The level of hemoglobin (Hb) was considered as the quality indicator for anemia, the target being an Hb level >11 g/dL, for UK centres the target was >10 g/dL. All new patients commencing hemodialysis between October 2003 and September 30, 2004 with the previous follow-up of less than one month and without previous blood transfusion were considered. A total of 902 patients were enrolled. The study showed that 4 to 6% of the Italian, Portuguese and British patients treated in FME clinics received a blood transfusion during the first year of follow-up. This is consistent with reports by USRDS that only 3.3% of ESRD patients received at least 1 transfusion per quarter in 1992 after erythropoietin became available and was prescribed to 88% of patients. About 18% Turkish patients, required blood transfusions during the first year of follow-up on hemodialysis, which is more comparable with USRDS data reported in 1989, when 16% of patients needed at least 1 transfusion quarterly. In conclusion, the practice of blood transfusion for hemodialysis patients is still frequent especially in elderly patients.
authors.affiliation: NephroCare Italy, Via Francesco Giordani 21/23, Naples, Italy. attilio.dibenedetto@fmc-ag.com
authors.forename: Attilio
authors.initials: A
authors.lastname: Di Benedetto
authors.forename: Nick
authors.initials: N
authors.lastname: Richards
authors.forename: Daniele
authors.initials: D
authors.lastname: Marcelli
authors.forename: Ali
authors.initials: A
authors.lastname: Basci
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cesare
authors.forename: Pedro
authors.initials: P
authors.lastname: Ponce
authors.forename: Laura
authors.initials: L
authors.lastname: Scatizzi
authors.forename: Paolo
authors.initials: P
authors.lastname: Marotta
mesh_terms: D000368:Aged; D000740:Anemia / Q000378:metabolism / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D001803:Blood Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D019983:Guideline Adherence; D006305:Health Status Indicators; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D017410:Practice Guidelines as Topic; D011786:Quality Control; D006435:Renal Dialysis; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D015415:Biomarkers; D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin